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Chronic viral infections of the hematopoietic system
are associated with bone marrow dysfunction, to
which both virus-mediated and immune-mediated
effects may contribute. Using unresolving noncyto-
pathic Friend virus (FV) infection in mice, we showed
that unregulated CD4+ T cell response to FV caused
IFN-g-mediated bone marrow pathology and anemia.
Importantly, bone marrow pathology was triggered by
relative insufficiency in regulatory T (Treg) cells and
was prevented by added Treg cells, which sup-
pressed the local IFN-g production by FV-specific
CD4+ T cells. We further showed that the T cell recep-
tor (TCR) repertoire of transgenic Treg cells express-
ing the b chain of an FV-specific TCR was virtually
devoid of FV-specific clones. Moreover, anemia in-
duction by virus-specific CD4+ T cells was efficiently
suppressed by virus-nonspecific Treg cells. Thus,
sufficient numbers of polyclonal Treg cells may pro-
vide substantial protection against bone marrow
pathology in chronic viral infections.
INTRODUCTION
A cardinal feature of adaptive immunity is that its response to
infection is proportional to the pathogen load and antigen pre-
sentation, which regulate the expansion and contraction of anti-
gen-specific lymphocytes (Zinkernagel and Hengartner, 2001).
An effective immune response, which leads to pathogen control
or clearance, is therefore self-limiting. Conversely, strong and
lasting immune responses, which are ineffective in pathogen
clearance, may be damaging to the host (Zinkernagel and Hen-
gartner, 2001). Excessive or ineffective immune responses are
characteristic of certain chronic viral infections, and their control782 Immunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc.is essential for the prevention of host tissue damage (Welsh and
Selin, 2002; Zinkernagel, 2002; Guidotti and Chisari, 2006). Thus,
several different mechanisms may operate, separately or in
concert, to limit immune pathology. Exposure of T cells to high
and persistent antigen loads has been shown to result in func-
tional exhaustion or physical loss of antigen-specific T cells
(Moskophidis et al., 1993; Zajac et al., 1998). The reactivity of
antigen-specific T cells can also be actively regulated by potent
suppressive mediators or specialized cell types, such as natu-
rally occurring regulatory T (Treg) cells (Mills, 2004; Rouse
et al., 2006; Belkaid, 2007).
Although many different cell types have been reported to exert
inducible immune-suppressive activity (Shevach, 2006), Treg
cells appear to be the largest subset in the body with naturally
endowed suppressive activity (Sakaguchi, 2004; Kronenberg
and Rudensky, 2005; Fontenot and Rudensky, 2005; Picca
et al., 2006). Treg cells make up a substantial proportion
(10%) of MHC class II-restricted CD4+ T cells and although
they share many molecular markers with conventional CD4+
T cells, they also express subset-defining markers, such as fork-
head box P3 (FoxP3), which directs Treg cell development and
function (Sakaguchi, 2004; Fontenot and Rudensky, 2005). Ac-
quisition of FoxP3 expression and phenotypic and functional
conversion to Treg cells has been demonstrated in conventional
naive CD4+ T cells, stimulated under predefined in vitro or in vivo
conditions (Shevach, 2006). However, the Treg cell population
found naturally in unmanipulated mice is almost exclusively of
thymic origin (Sakaguchi, 2004; Fontenot and Rudensky, 2005;
Pacholczyk et al., 2006), indicating that peripheral conversion
of naive CD4+ T cells is very rare in steady-state conditions.
Similarly to conventional CD4+ T cells, in which induction of
effector function requires antigenic stimulation, stimulation
through the T cell receptor (TCR) is also considered necessary
to induce suppressive function in Treg cells (Sakaguchi, 2004;
von Boehmer, 2005). However, Treg cell-mediated suppression,
once induced, can be directed toward T cells of unrelated spec-
ificity and is therefore antigen nonspecific (Thornton and
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Treg Cell Specificity in Retroviral InfectionFigure 1. T Cell Reactivity to env122–141 and TCR Va2 Usage in EF4.1 TCRb-Transgenic Mice
(A) Flow-cytometric example of CD69 and CD40L induction in CD4+ EF4.1 TCRb-transgenic T cells 18 hr after stimulation with the env122–141 peptide.
(B) Mean (±SEM) percentage of responding cells in total CD4+ T cells from EF4.1 TCRb-transgenic or wild-type control mice 18 hr after stimulation.
(C) Mean (±SEM) percentage of responding cells in gated TCR Va2+ or Va2 CD4+ T cells from EF4.1 TCRb-transgenic 18 hr after stimulation.
(D) Mean (±SEM) percentage of responding cells, plotted as a fraction of the maximal response, in gated TCR Va2+ or Va2 CD4+ T cells from EF4.1 TCRb-trans-
genic 18 hr after stimulation.
(E) TCR Va2+ T cells in responding (CFSE) or nonresponding (CFSE+) CD4+ T cells from EF4.1 TCRb-transgenic 3 days after stimulation. Values in (A)–(E)
are representative of five independent experiments.Shevach, 2000; von Boehmer, 2005). Elucidation of the antigenic
repertoire of Treg cells has been a matter of debate (Fontenot
and Rudensky, 2005; Picca et al., 2006). Analyses of TCR reper-
toires in mice have indicated that, in comparison with naive CD4+
T cells, the TCR repertoire of Treg cells is of equal or even higher
diversity, with a substantial number of clones found uniquely
in the Treg cell pool (Hsieh et al., 2004; Pacholczyk et al.,
2006; Wong et al., 2007). Although there are notable exceptions
(van Santen et al., 2004; Pacholczyk et al., 2007), most observa-
tions support a model in which relatively high-affinity recognition
of self-peptide-MHC II complexes favors thymic development
of Treg cells and skews their TCR repertoire toward recognition
of self-peptides (Hsieh et al., 2004; Sakaguchi, 2004; Fontenot
and Rudensky, 2005; Kronenberg and Rudensky, 2005; Picca
et al., 2006). However, despite their importance for immune
regulation, the nature of self-peptides recognized by Treg
cells or the degree of their reactivity to foreign peptides is still
unclear.
We have developed a system to study the pathological conse-
quences of the T helper cell response to unresolving infection
with Friend virus (FV), a murine retroviral complex, which causes
persistent infection of the hematopoietic system (Hasenkrug and
Chesebro, 1997). We showed that exuberant virus-specific CD4+
T cell response to FV infection resulted in bone marrow immune
pathology and anemia, the severity of which crucially depended
on the balance between FV-specific pathogenic CD4+ T cells
and Treg cells. Importantly, pathogenic CD4+ T cells and Treg
cells differed dramatically in their requirements for direct recog-
nition of viral antigens. Analysis of mice, in which transgenic
expression of the TCRb chain from a FV-specific CD4+ T cell
clone created a polyclonal TCR repertoire with increased
frequency of FV-specific CD4+ T cells, indicated that the TCR
repertoire of naturally occurring Treg cells in virus-naive mice
was virtually devoid of FV-specific clones. Nevertheless, bone
marrow pathology driven by FV-specific TCRb-transgenic
CD4+ T cells was efficiently suppressed by virus-nonspecific
Treg cells. Thus, virus-reactivity was neither detected in Treg
cells nor required for their suppressive function.RESULTS
TCRb-Transgenic Mice with Increased FV-Specific
T Helper Precursor Frequency
To study the response of virus-specific T helper cells to retroviral
infection, we have generated mice, here referred to as EF4.1,
transgenically expressing the TCRb chain of a TCR specific to
an MHC class II-presented epitope of the surface (SU) product
of the F-MuLV envelope (env) gene (Iwashiro et al., 1993). The
transgenic TCRb chain is able to associate with endogenous
TCRa chains creating a polyclonal repertoire. EF4.1 TCRb-trans-
genic CD4+ T cells responded to in vitro stimulation by an env
122–141 peptide (env122–141), by upregulating CD69 and
CD40L (Figures 1A and 1B). This response was linear over a 4-
log10 range of env122–141 concentration, suggesting a multiclonal
composition reaching on average a maximum of 4% env-spe-
cific T cells in total CD4+ T cells (Figure 1B). We next examined
the expression of particular endogenous TCR Va families in
responding EF4.1 TCRb-transgenic CD4+ T cells and identified
TCR Va2 as one that conferred specificity and higher than aver-
age avidity for env122-141 (Figures 1C and 1D). Compared with
their TCR Va2- counterparts, TCR Va2+ EF4.1 TCRb-transgenic
CD4+ T cells contained a higher frequency of env-specific
T cells (3% and 15%, respectively) (Figure 1C). Furthermore,
Va2+ env-specific CD4+ T cells were >30-fold more sensitive to
env122–141 than their Va2
 counterparts (ED50 = 0.04 mM and >
1.24 mM env122–141, respectively) (Figure 1D). As a result of differ-
ences in frequency and functional avidity for env122-141 between
virus-naive TCR Va2+ and Va2 env-specific T cells, TCR Va2+
T cells, which normally represent 12%–14% of all CD4+ T cells
in C57BL/6 (B6) mice, were highly enriched in the responding
population (40%–60% TCR Va2+) (Figure 1E).
T Helper Cell Response to Retroviral Infection Results
in Bone Marrow Pathology
To follow the immunopathological consequences of a continuous
FV-specific T helper cell response, we adoptively transferred
EF4.1 TCRb-transgenic CD4+ T cells, containing FV-specificImmunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc. 783
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Treg Cell Specificity in Retroviral Infectionclones, into FV-infected immunodeficient Rag1/ hosts, in
which the absence of CD8+ T cells or B cells prevents virus clear-
ance or control. Starting from the second week of transfer, recip-
ient mice developed symptoms of anemia reflected in red blood
cell (RBC) counts in peripheral blood (Figure 2A). Anemia peaked
on day 21 after adoptive transfer of EF4.1 TCRb-transgenic
CD4+ T cells and remained chronic with only modest recovery
at later time points (Figure 2A). In contrast to concurrent transfer
of EF4.1 TCRb-transgenic CD4+ T cells and FV infection, neither
EF4.1 TCRb-transgenic CD4+ T cell transfer nor FV infection
alone produced any substantial signs of anemia in the recipient
mice in the time frame of these experiments (Figure 2A). These
results suggest that anemia in this setting is a pathological
consequent of the T helper response to FV infection, rather
than FV infection itself.
To determine whether anemia was the result of reduced bone
marrow function, we examined the cellularity and composition of
the bone marrow in anemic mice. Neither FV infection nor EF4.1
TCRb-transgenic CD4+ T cell transfer had any appreciable effect
on bone marrow cellularity (Figure 2B–2D) or composition (Fig-
ure 2E–2G). In contrast, EF4.1 TCRb-transgenic CD4+ T cell
transfer in FV-infected recipients caused significant reduction
in total bone marrow cell numbers (Figure 2B). This effect was
more pronounced in Ter119+ erythroid precursors (Figure 2C),
but also observed in the heterogeneous population of
CD11b+Gr1+ myeloid precursors (Figure 2D), which together
represent 75% of bone marrow cells in Rag1/ mice. Further-
more, EF4.1 TCRb-transgenic CD4+ T cell transfer in FV-infected
recipients was associated with significant functional reduction in
hematopoietic colony-forming cells (Figures S1A and S1B avail-
able online) and histological hypocellularity with pronounced re-
duction in hyperchromatic normoblasts (Figure S1C), consistent
with generalized myelosuppression. In FV-infected mice, two-
thirds and one-third of Ter119+ and CD11b+Gr1+ bone marrow
cells, respectively, were positive for the glycosylated product
of the viral gag gene (glyco-Gag), an indicator of FV infection
(Figure 2F). However, this was not associated with any bone
marrow dysfunction, in line with the noncytopathic nature of FV
infection. Transfer of FV-specific CD4+ T cells in FV-infected
mice led to marked reduction in the number of infected bone
marrow cells (Figure 2G), in agreement with the reported direct
antiviral activity of FV-specific CD4+ T cells, mediated by IFN-g
(Iwashiro et al., 2001). However, substantial numbers of FV-
infected cells remained present (Figure 2G), indicating incom-
plete virus control by FV-specific CD4+ T cells in the absence
of CD8+ T cells and B cells.
Expansion of transferred EF4.1 TCRb-transgenic CD4+ T cells
in the spleens of FV-infected Rag1/ hosts was only marginally
higher than homeostatic expansion of the same cells in the
spleens of uninfected Rag1/ hosts (Figures 2H and 2I). Inter-
estingly, expansion in response to FV infection, but not homeo-
static expansion, was associated with enrichment of CD4+
T cells in TCR Va2+ clones (Figure 2H). In contrast to homeostatic
expansion in the spleen, significant numbers of transferred EF4.1
TCRb-transgenic CD4+ T cells were found in the bone marrow of
Rag1/ hosts only in the presence of FV infection (Figures 2J
and 2K). CD4+ T cells isolated from the bone marrow of FV-
infected recipients were also highly enriched in TCR Va2+ clones
(Figure 2J). Together, these results support a model in which fail-784 Immunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc.ure to contain noncytopathic FV infection in Rag1/ hosts at-
tracted FV-specific CD4+ T cells to the bone marrow, a location
from which they were normally excluded, ultimately leading to
bone marrow pathology. In support of this model, FV infection
was also found in the bone marrow of B cell-deficient mice,
which lack FV-neutralizing antibodies, but not of wild-type con-
trol mice (Figure S2A). Furthermore, in contrast to wild-type
mice, B cell-deficient mice experienced significant anemia dur-
ing FV infection (Figure S2B). Because B cell-deficient mice
were T cell replete, these results indicated that, first, the contri-
bution of immunodeficient hosts to anemia development was
to allow the spread of FV replication to the bone marrow, rather
than to provide a state of T cell-lymphopenia, and second, both
EF4.1 TCRb-transgenic and wild-type host T cells were capable
of mediating bone marrow pathology in this setting.
Treg Cells Suppress FV-Induced
Bone Marrow Pathology
The development of aplastic anemia in FV-infected Rag1/ re-
cipients of EF4.1 TCRb-transgenic CD4+ T cells highlighted the
pathogenic potential of FV-specific clones. However, donor
CD4+ T cells should also contain Treg cells, which would coun-
teract the pathogenic effect of excessive T helper response to
FV infection. We first confirmed that development of Treg cells
was not perturbed in EF4.1 TCRb-transgenic mice. As expected
in mice transgenic for a TCR with bias for MHC class II recogni-
tion, there was an increase in absolute numbers of naive CD4+
T cells (Figure 3A). In both wild-type and EF4.1 TCRb-transgenic
CD4+ T cells, expression of CD25 overlapped with expression of
Treg cell-specific transcription factor FoxP3 (Figure 3B) and the
absolute numbers of Treg cells were comparable between the
two groups of mice (Figure 3A). However, the percentage of
Treg cells in total CD4+ T cells was reduced in EF4.1 TCRb-trans-
genic mice, in comparison with wild-type mice, because of the
increase in naive CD4+ T cells (Figures 3A and 3B).
To examine whether Treg cells in the transferred EF4.1 TCRb-
transgenic CD4+ T cell population were working against pathol-
ogy-inducing FV-specific T cells, we compared transfers of total
CD4+ T cells with transfers of Treg-depleted naive CD4+ T cells.
RBC counts in recipients of naive CD4+CD45RBhiCD25 EF4.1
TCRb-transgenic T cells dropped significantly lower than in re-
cipients of total CD4+ T cells, reaching their lowest value on
day 21 after T cell transfer, which was followed by partial recov-
ery to counts comparable to those in recipients of total CD4+
T cells by day 35 (Figure 3C). Thus, the overall severity of anemia
was exacerbated by removal of Treg cells from the transferred
CD4+ T cell population. We therefore reasoned that supplement-
ing the total CD4+ T cell population with additional Treg cells
would have a protective effect against bone marrow pathology.
Indeed, addition of extra EF4.1 TCRb-transgenic Treg cells led
to substantial, albeit incomplete, suppression of anemia devel-
opment (Figure 3C). Suppression of anemia by Treg cells was
also accompanied by restoration of numbers of Ter119+ (Fig-
ure 3D) and CD11b+Gr1+ bone marrow cells (Figure 3E), indicat-
ing that Treg cells were acting by reducing bone marrow pathol-
ogy. Thus, the severity of bone marrow pathology during the
CD4+ T cell response to unresolving FV infection appeared to
be directly proportional to the relative frequency of Treg and
pathogenic T cells.
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Treg Cell Specificity in Retroviral InfectionFigure 2. Continuous T Helper Cell Response to Unresolving FV Infection Causes Bone Marrow Pathology
(A) Changes in RBC counts in Rag1/ mice, which were infected with FV (FV only) or received EF4.1 TCRb-transgenic CD4+ T cells (T cells only), or both
(T cells + FV). Values represent the mean (±SEM) of 8–18 mice per group per time point, analyzed in more than three independent experiments. p < 0.001
between ‘‘T cells + FV’’ group and all other groups for days 14–35.
(B–D) Total bone marrow cellularity (B) and numbers of Ter119+ erythroid precursor cells (C) and CD11b+Gr1+ bone marrow cells (D) in the same recipient mice.
The dashed line represents the average cell numbers of untreated Rag1/ mice. Values are the mean (±SEM) of 5–13 mice per group on day 21. Numbers within
the graphs denote the p values.
(E–G) Percentages of uninfected and FV-infected (glyco-Gag+) Ter119+ and CD11b+Gr1+ cells in the bone marrow of the same groups of mice described in (A).
Numbers within the plots represent the percentage of positive cells are the average of more than five mice per group analyzed on day 21.
(H–K) Percentage (H and J) and absolute numbers (I and K) of CD4+ T cells and percentage of TCR Va2+ T cells in total CD4+ T cells (H and J) in the spleen (H and
I) or the bone marrow (J and K) of uninfected (FV) or FV-infected (+FV) recipients of EF4.1 TCRb-transgenic CD4+ T cells. Values are representative of 5–8 mice
per group analyzed on day 21.Immunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc. 785
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Treg Cell Specificity in Retroviral InfectionFigure 3. Suppression of Bone Marrow Pathology by Treg Cells in a Dose-Dependent Manner
(A) Absolute numbers of naive CD44loCD25, memory (mem.) CD44hiCD25 or regulatory (reg.) CD25+ CD4+ T cells in secondary lymphoid organs of EF4.1
TCRb-transgenic (TCRb-tg) and wild-type control mice. Values are the mean (±SEM) of six mice per group and numbers within the graphs denote the p value.
(B) CD25 and FoxP3 staining in gated CD4+ T cells from EF4.1 TCRb-transgenic (TCRb-tg) and wild-type control mice. Numbers within the quadrants denote the
percentages of positive cells and are representative of three mice per group.
(C) Changes in RBC counts in FV-infected Rag1/ mice, which received total EF4.1 TCRb-transgenic CD4+ T cells (Ttotal), FACS-purified Treg-depleted naive
CD45RBhiCD25CD4+ T cells (Tnaive), or total CD4+ T cells together with FACS-purified CD25+ CD4+ T cells at 1:1 ratio (Ttotal + Treg). Values represent the mean
(±SEM) of 8–12 mice per group per time point analyzed in three independent experiments. p = 0.0002 between ‘‘Ttotal’’ and ‘‘Ttotal + Treg,’’ and p = 0.00002
between ‘‘Ttotal’’ and ‘‘Tnaive,’’ on day 21.
(D and E) Numbers of Ter119+ erythroid precursor cells (D) and CD11b+Gr1+ bone marrow cells (E) in FV-infected Rag1/ mice, which received EF4.1 TCRb-
transgenic CD4+ T cells, alone or together with EF4.1 TCRb-transgenic Treg cells at 1:1 ratio. The dashed line represents the average cell numbers of untreated,
uninfected Rag1/ mice. Values are the mean (±SEM) of 5–8 mice per group on day 21. Numbers within the graphs denote the p values.Treg Cells Limit IFN-g Production by Pathogenic T Cells
To further investigate the mechanisms by which FV-induced
bone marrow pathology was suppressed by Treg cells, we
examined their effect on the expansion and effector function of
FV-specific pathogenic T cells. Addition of EF4.1 TCRb-trans-
genic Treg cells caused a 50% reduction in the expansion of
CD4+ T cells in the spleens of FV-infected recipients (Figure S3A).
However, Treg cells did not prevent the enrichment of the
expanded CD4+ T cells in TCR Va2+ clones (Figure S3B),
suggestive of preferential expansion of FV-specific clones.
More importantly, addition of Treg cells did not prevent the
migration, accumulation, or local expansion of CD4+ T cells
(Figure S3C) or the preferential expansion of FV-specific TCR
Va2+ clones in the bone marrow (Figure S3D). These results indi-
cated that Treg cells acted on a subsequent step of pathology in-
duction by CD4+ T cells, such as effector cytokine production.
IFN-g was the major cytokine produced by the transferred
CD4+ T cells (Figures 4A–4D), and because this cytokine has
an established role in myelosuppression (Raefsky et al., 1985),
we examined its role in this model. The additional Treg cells
caused, on average, 20% reduction in the percentage of splenic
CD4+ T cells able to produced IFN-g upon in vitro restimulation
(Figures 4A and 4B). The effect of Treg cells on elicited IFN-g pro-
duction by bone marrow CD4+ T cells was more dramatic, in
which they caused 45% reduction in the percentage of IFN-g
producing cells (Figures 4C and 4D). Furthermore, Treg cells
had a profound effect on the amount of IFN-g produced by indi-
vidual bone marrow CD4+ T cells, on the basis of the median
fluorescent intensity (MFI) of the IFN-g staining, which was
reduced by 34% (Figure 4C). The effect of Treg cells on CD4+
T cell production of IFN-g was also evident in IFN-g serum con-
centration, which was reduced by 40% (Figure 4E). Thus, Treg
cells appeared to be limiting CD4+ T cell production of IFN-g,
especially in the local bone marrow environment.786 Immunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc.To determine a possible pathogenic role for IFN-g in FV-
induced bone marrow pathology, we used as recipients mice de-
fective in IFN-g receptor signaling. In comparison to FV-infected
Rag1/ recipients of EF4.1 TCRb-transgenic CD4+ T cells, ane-
mia development in FV-infected Rag1/Ifngr1/ recipients
was absent or markedly delayed, demonstrating an essential
role for IFN-g signaling in this process (Figure 4F). Late onset
of anemia in Rag1/Ifngr1/ was accompanied by develop-
ment of myeloid leukemia specifically in these hosts, thereby
necessitating termination of these experiments. Collectively,
these results established a mechanism for virus-specific CD4+
T cell-induced anemia in FV-infected Rag1/ hosts and its sup-
pression by Treg cells.
The Virus-Naive TCR Repertoire of Treg Cells
Is Devoid of Virus-Reactive Clones
The pathology-inducing response of EF4.1 TCRb-transgenic
CD4+ T cells required activation of FV-specific clones by FV in-
fection, given that it did not develop in uninfected recipients. It
was therefore of interest to establish whether the suppressive re-
sponse of EF4.1 TCRb-transgenic Treg cells also required acti-
vation of FV-specific Treg cell clones during infection or whether
this effect was mediated by Treg cells of unrelated specificity.
We first confirmed usage of the transgenic TCRb chain in regu-
latory CD4+ T cells in EF4.1 TCRb-transgenic mice, by measur-
ing the degree of allelic exclusion of endogenous TCRb chains.
Expression of endogenous TCRb chains was found in 22% of
Treg cells, which also displayed higher expression of CD44
than the bulk of Treg cells (Figure S4), suggesting that, similarly
to memory CD4+ T cells, they may be the result of the exposure
to diverse environmental antigens (Fisson et al., 2003). Neverthe-
less, the TCRb transgenic chain was used by the majority (78%)
of Treg cells in EF4.1 TCRb-transgenic mice, and it was therefore
possible that in some of them it conferred env specificity.
Immunity
Treg Cell Specificity in Retroviral InfectionFigure 4. Treg-Mediated Suppression of Local IFN-g Production by Conventional EF4.1 TCRb-Transgenic CD4+ T Cells in the Bone Marrow
(A–D) Percentage of IL-17A and IFN-g producing cells in total CD45.1+ EF4.1 TCRb-transgenic CD4+ T cells, isolated from the spleen (A and B) or the bone marrow
(C and D) of FV-infected Rag1/ mice, which received total CD45.1+ EF4.1 TCRb-transgenic CD4+ T cells, alone () or together (+ Treg) with CD45.2+ EF4.1
TCRb-transgenic Treg cells at 1:1 ratio. Values are representative of six to nine mice per group, analyzed either on day 21 or day 35 with identical results. Numbers
within the bar graphs and dot plots denote the p values and percentage of positive cells, respectively. The median fluorescence intensity (MFI) ± SEM of IFN-g
staining in C was ‘‘ Treg’’ = 160 ± 19; ‘‘+ Treg’’ = 105 ± 15; p = 0.0003, Student’s t test, n = 6.
(E) Serum IFN-g concentration in FV-infectedRag1/mice, which received total CD45.1+ EF4.1 TCRb-transgenic CD4+ T cells, alone () or together (+ Treg) with
CD45.2+ EF4.1 TCRb-transgenic Treg cells at 1:1 ratio. Values represent the mean (±SEM) of four to five mice per group analyzed on day 35. The dashed line
depicts the basal concentration of serum IFN-g in unmanipulated Rag1/ mice. Numbers within the graph denote the p values.
(F) Changes in RBC counts in Rag1/Ifngr1+/+ (Ifngr1+/+) or Rag1/Ifngr1/ (Ifngr1/) mice either infected with FV alone (Ifngr1+/+; Ifngr1/) or infected with
FV and received CD4+ T cells (Ifngr1+/+ + T cells; Ifngr1/ + T cells). Values represent the mean (±SEM) of 12–15 mice per group per time point analyzed in three
independent experiments. p < 0.0001 between ‘‘Ifngr1+/+ + T cells’’ and ‘‘Ifngr1/ + T cells,’’ on days 14 and 21.To test whether Treg cells in EF4.1 TCRb-transgenic mice
contained any env-specific clones, we examined their potential
to suppress a responding CD4+ T cell population in an env-
specific manner in vitro. CD3-stimulated EF4.1 TCRb-trans-
genic Treg cells were able to efficiently suppress the prolifera-
tion (Figure 5A) and completely inhibited IL-2 production
(Figure 5B) by CD3-stimulated EF4.1 TCRb-transgenic naive
CD4+ T cells, demonstrating potent suppressive function by
EF4.1 TCRb-transgenic Treg cells. In contrast, env122–141-stim-
ulated EF4.1 TCRb-transgenic Treg cells had no effect on the
proliferation (Figure 5C) and only a small effect on IL-2 produc-
tion (Figure 5D) by env122–141-stimulated EF4.1 TCRb-trans-
genic naive CD4+ T cells. The small apparent effect of Treg cells
on IL-2 production by env-specific naive CD4+ T cells was
probably due to IL-2 consumption resulting from the high ratio
of total Treg cells (50% of culture T cells) to env-specific T cells
(2% of culture T cells) in these conditions. Together, these
findings suggested lack of specific induction of suppressive
function in EF4.1 TCRb-transgenic Treg cells by the env122–141
peptide.
To test the env reactivity of EF4.1 TCRb-transgenic Treg cells
more directly, we measured their proliferative response to
env122–141 presented by dendritic cells, under conditions previ-
ously shown to expand antigen-specific Treg cells (Yamazaki
et al., 2003). Treg cell-depleted CD25CD4+ EF4.1 TCRb-trans-
genic T cells responded specifically to env122–141 stimulation by
proliferating far more extensively than the spontaneous prolifer-
ation seen upon Treg cell removal in the absence of peptide or in
the presence of the unrelated ova323–339 peptide (Figure 5E). In
contrast, no proliferation of EF4.1 TCRb-transgenic Treg cells
was seen after stimulation with either peptide (Figure 5E). As
a control for the efficiency of in vitro stimulation of Treg cells,
we used CD25CD4+ T cells and Treg cells from ovalbumin(ova)-specific OT-II TCR-transgenic mice, which carry TCRa
and TCRb transgenes. Notably, the combination of transgenic
TCRa and TCRb expression was found in almost all naive
CD4+ T cells, but only 22% of Treg cells from OT-II TCR-trans-
genic mice (Figure S5), indicating that reactivity to this foreign
antigen (ova) was underrepresented in the Treg cell TCR reper-
toire even in TCRa and TCRb doubly transgenic mice. However,
because TCRa was not subject to allelic exclusion, the relatively
small population of Treg cells expressing the OT-II TCRb trans-
gene was ova specific and proliferated to ova323–339, but not
env122–141 stimulation under these experimental conditions
(Figure 5F). Thus, the EF4.1 TCRb-transgenic Treg cell TCR
repertoire appeared to lack clones able to respond to in vitro
stimulation with the env122–141 peptide, and such a finding is in
line with observations that the TCR repertoire of natural Treg
cells is biased toward recognition of self-peptides (Hsieh et al.,
2004).
To directly visualize env-specific clones in polyclonal EF4.1
TCRb-transgenic CD4+ T cells, we stained these cells with
MHC class II Ab-env122–141 tetramers (A
b-env). Although binding
to this reagent is specific to env-reactive clones (MacLeod et al.,
2006), binding is also a function of TCR affinity (Crawford et al.,
1998) and Ab-env tetramer binding is restricted only to env-
specific clones with a relatively high functional avidity. Indeed,
a small fraction of TCRb-transgenic, but not wild-type control,
CD4+ T cells were Ab-env+ (Figure 5G). Importantly, Ab-env+
clones were found exclusively in the conventional CD25CD4+
T cell subset (Figure 5G). Compared with the bulk Ab-env
CD4+ T cell population, Ab-env+ CD4+ T cells were enriched in
naive T cells but devoid of Treg cells (Figure 5H). These results
showed that env-specific clones with TCR affinity high enough
for Ab-env binding were absent from the TCR repertoire of
EF4.1 TCRb-transgenic Treg cells.Immunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc. 787
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(A–D) CFSE dilution profile of conventional EF4.1 TCRb-transgenic CD4+ T cells (A and C) and IL-2 concentration in supernatants (B and D) of cultures of CD45.1+
naive CD45RBhiCD25 EF4.1 TCRb-transgenic CD4+ T cells, with (+ Treg) or without an equal number of CD45.2+ CD25+ EF4.1 TCRb-transgenic Treg cells,
stimulated either with anti-CD3 (A and B) or with the env122-141 peptide (C and D) presented by bone marrow-derived dendritic cells. IL-2 concentration and
CFSE profiles were assayed on days 2 and 3 of culture, respectively. Specifically for env122–141 peptide stimulation, the CFSE profile of responding cells only
is shown. No differences in the fraction of responding cells were observed in the presence or absence of Treg cells. Numbers within the plots denote the
mean division number of responding cells.
(E and F) CFSE dilution profile of purified CD25 or CD25+ EF4.1 TCRb-transgenic (E) or OT-II TCRab-transgenic (F) CD4+ T cells, 5 days after stimulation by bone
marrow-derived dendritic cells in the absence of specific peptides () or presenting either env122–141 or ova323–339 peptides. Numbers within the quadrants
represent the percentage of divided cells. One experiment, representative of four similar experiments, is shown.
(G) Ab-env tetramer staining and CD25 expression in gated CD4+ T cells from wild-type and EF4.1 TCRb-transgenic mice. Numbers within the quadrants indicate
the percentage of positive cells.
(H) Percentage of naive, memory (mem.), and regulatory (reg.) cells in gated Ab-env or Ab-env+ EF4.1 TCRb-transgenic CD4+ T cells. Numbers within the graph
denote the p values. Data were obtained from four mice per group.Suppression of Bone Marrow Pathology
by env-Nonspecific Treg Cells
Virus-naive EF4.1 TCRb-transgenic Treg cells appeared to lack
env-specific clones, yet they efficiently suppressed the develop-
ment of bone marrow pathology induced by FV-infection. We
therefore addressed whether suppression of FV-induced pathol-
ogy was mediated by in vivo expansion of a small number of FV-
specific EF4.1 TCRb-transgenic Treg cells, the initial frequency
of which may have been too low to measure with the methods
we employed. EF4.1 TCRb-transgenic Treg cells were compared
with nontransgenic control Treg cells, in which env-specific
clones would be at a much lower frequency or absent. Expansion
of CD45.2+ EF4.1 TCRb-transgenic and wild-type Treg cells was
comparable, and both reached similar proportions of total CD4+
T cells in cotransfers with pathogenic CD45.1+ EF4.1 TCRb-
transgenic CD4+ T cells, in the spleen (Figure 6A) and the bone
marrow (Figure 6B) of FV-infected recipients. Furthermore, in
contrast to pathogenic EF4.1 TCRb-transgenic CD4+ T cells788 Immunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc.(Figure S3), neither EF4.1 TCRb-transgenic nor wild-type Treg
cells showed any enrichment for TCR Va2+ clones (Figures 6A
and 6B), indicating that their expansion was polyclonal and not
skewed by expansion of env-specific clones. More importantly,
wild-type Treg cells were able to suppress induction of anemia
by pathogenic FV-specific CD4+ T cells, with efficiency similar
to EF4.1 TCRb-transgenic Treg cells (Figure 6C). Suppression
of bone marrow pathology by wild-type Treg cells was not the
result of selective expansion of env-specific clones because, in
contrast to pathogenic EF4.1 TCRb-transgenic CD4+ T cells,
half of which stained brightly with the Ab-env tetramer, no-Ab-
env+ cells were found in expanded wild-type Treg cell population
(Figure 6D). Thus, suppression of FV-specific CD4+ T cell-
induced bone marrow pathology was mediated by Treg cells
independently of shared antigenic specificity.
Although suppression of anemia development depended on
the cotransfer of env-nonspecific Treg cells, it was possible
that env-specific Treg cells were generated de novo from EF4.1
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T Cell-Induced Bone Marrow Pathology by
env-Nonspecific Treg Cells
(A and B) Percentage of CD45.2+ CD4+ Treg cells
in total CD4+ T cells (top row) and percentage of
TCR Va2+ T cells in CD45.2+ CD4+ Treg cells (bot-
tom row), in the spleen (A) or the bone marrow (B)
of FV-infected Rag1/ recipients, after cotransfer
of CD45.1+ EF4.1 TCRb-transgenic total CD4+
T cells with either EF4.1 TCRb-transgenic (TCRb-
tg) or wild-type CD45.2+ CD25+ CD4+ Treg cells,
at 1:1 ratio. Numbers within the plots indicate the
percentage of positive cells and are representative
of six to eight mice per group, analyzed on day 21
after transfer.
(C) Changes in RBC counts in FV-infectedRag1/
mice, which received total EF4.1 TCRb-transgenic
CD4+ T cells, alone (Ttotal) or together with either
EF4.1 TCRb-transgenic (Ttotal + tg Treg) or wild-
type (Ttotal + wt Treg) CD25+ CD4+ Treg cells.
Values represent the mean (±SEM) of six to ten
mice per group per time point analyzed in three
independent experiments. p < 0.0003 between
‘‘Ttotal’’ and either ‘‘Ttotal + tg Treg’’ or ‘‘Ttotal +
wt Treg’’ on day 21.
(D) Ab-env tetramer staining in CD4+ T cells from
the spleen or the bone marrow of FV-infected
Rag1/ recipients, after cotransfer of CD45.1+
EF4.1 TCRb-transgenic total CD4+ T cells with
CD45.2+ wild-type CD25+ CD4+ Treg cells, at 1:1
ratio. Numbers within the quadrants indicate the
percentage of tetramer positive cells in either
CD45.1+ or CD45.2+ CD4+ T cells and are repre-
sentative of four mice per group, analyzed on
day 21 after transfer.
(E) Changes in RBC counts in FV-infected Rag1/ mice, which received either total CD4+ T cells (wt Ttotal) or purified naive CD45RBhiCD25 CD4+ T cells
(wt Tnaive) from wild-type donor mice or no T cells (no cells). Values represent the mean (±SEM) of nine to ten mice per group per time point analyzed in two
independent experiments. p < 0.0003 between ‘‘wt Tnaive’’ and ‘‘wt Ttotal,’’ on day 21.TCRb-transgenic CD4+ T cells during infection and contributed to
disease suppression. Furthermore, although Treg cells com-
pletely lacked env specificity, they may have reacted to other
FV-encoded epitopes. For evaluation of induction of FoxP3
expression in FV-specific CD4+ T cells responding to infection,
EF4.1 TCRb-transgenic mice were crossed to a FoxP3EGFP re-
porter strain, Foxp3egfp (Wang et al., 2008) (Figure S6A). Despite
marked expansion in response to FV infection (Figure S6B), no
FoxP3 expression was detected in purified FoxP3 (GFP)
CD45.1+ EF4.1 TCRb-transgenic Foxp3egfp CD4+ T cells adop-
tively transferred into FV-infected B6 recipients (Figure S6C).
Similarly, no FoxP3 expression was detected in purified FoxP3
(GFP) CD45.1+ EF4.1 TCRb-transgenic Foxp3egfp CD4+ T cells
cotransferred with CD45.2+ wild-type Treg cells into FV-infected
Rag1/ recipients (Figure S6D). Furthermore, FV infection did
not expand any Treg cell subpopulation with potential FV reactiv-
ity because no in vitro proliferative response to dendritic cells
pulsed with env122–141 or whole FV could be seen in Treg cells iso-
lated from the spleens of FV-infected B6 mice (Figure S7A) or the
bone marrow of FV-infected Rag1/ recipients of EF4.1 TCRb-
transgenic CD4+ T cells and wild-type Treg cells (Figure S7B).
Therefore, FV infection did not induce the expansion of pre-exist-
ing Treg cells or the conversion into Treg cells of CD4+ T cells,
which were able to respond to FV-encoded env or other potential
epitopes.Our data indicated that development of anemia in this model
was caused by FV-specific CD4+ T cells but could be suppressed
by any Treg cell population, regardless of FV reactivity. If so, then
CD4+ T cells from nontransgenic wild-type donors, in which the
frequency of FV-specific pathogenic clones would be physiologi-
cally very low (<105) but the frequency of Treg cells is normal
(101), should not induce anemia. However, removal of Treg cells
fromthispopulationshouldunmask the pathogenicpotential of the
relative infrequent FV-specific clones. Indeed, in contrast to total
CD4+ T cells from EF4.1 TCRb-transgenic mice (Figure 2A), those
from wild-type mice failed to induce severe anemia upon transfer
into FV-infected Rag1/ recipients (Figure 6E). Importantly, Treg
cell depletion allowed naive wild-type CD4+ T cells to induced ane-
mia in FV-infected recipients (Figure 6E), the severity of which was
milder than anemia induced by naive EF4.1 TCRb-transgenic
CD4+ T cells, in line with the reduced frequency of FV-specific
clones in the former population. Thus, development of bone mar-
row pathology under these experimental conditions crucially
depended on the relative frequency of conventional CD4+ T cells
with FV specificity and Treg cells independently of FV specificity.
Potential Mechanisms of Treg Cell Activation
and Action in FV Infection
Nonshared antigen specificity between pathogenic CD4+ T cells
and Treg cells suggested a broad mode of Treg cell-mediatedImmunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc. 789
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(A) Changes in RBC counts in FV-infectedRag1/mice, which received either no T cells (no cells) or total EF4.1 TCRb-transgenic CD4+ T cells either alone (Ttotal)
or together with wild-type (Ttotal + wt Treg) or IL-10-deficient CD25+ CD4+ Treg cells (Ttotal + Il10/ Treg). Values represent the mean (±SEM) of five to six mice
per group per time point analyzed in a single experiment. p < 0.001 and p < 0.02 between ‘‘Ttotal’’ and ‘‘Ttotal + Il10/ Treg,’’ on days 14 and 21, respectively; the
p value was not significant between ‘‘Ttotal + wt Treg’’ and ‘‘Ttotal + Il10/ Treg.’’
(B) Expression of individual endogenous TCR Vb5.1/5.2, Vb6, Vb8.1/8.2, Vb11, and Vb14 chains in EF4.1 TCRb-transgenic Treg cells recovered from the lymph
nodes (LNs), the spleen (SP) or the bone marrow (BM) of uninfected ( FV) or FV-infected (+ FV) Rag1/ recipients, which received CD45.2+ EF4.1 TCRb-trans-
genic CD25+ CD4+ Treg cells together with CD45.1+ EF4.1 TCRb-transgenic total CD4+ T cells, at 1:1 ratio. Expression in EF4.1 TCRb-transgenic Treg cells before
(input) and 21 days after transfer (recovered) is shown. Values represent the mean (±SEM) of two to four individual recipients from a single experiment.
(C) CFSE dilution profile of CD45.1+ CD4+ Treg cells in the lymph nodes (LN), spleen (SP), and bone marrow (BM) of FV-infected Rag1/ recipients, which re-
ceived CD45.2+ EF4.1 TCRb-transgenic total CD4+ T cells, at the time of FV infection, and a second cohort of CFSE-labeled CD45.1+ wild-type CD25+ CD4+ Treg
cells 21 days later. Organs were analyzed 3 days after transfer of the second Treg cell cohort. Numbers within the quadrants denote the percentage of undivided
cells and are representative of four mice analyzed in two separate experiments. p < 0.007 between ‘‘BM’’ and either ‘‘LN’’ or ‘‘SP.’’
(D and E) Absolute number of CD45.2+ Treg cells recovered from the spleen (D) or the bone marrow (E) of uninfected ( FV) or FV-infected (+ FV) Rag1/
recipients, which received CD45.2+ wild-type CD25+ CD4+ Treg cells alone ( Te cells) or together with CD45.1+ EF4.1 TCRb-transgenic total CD4+ T cells at
1:1 ratio (+ Te cells). Values represent the mean (±SEM) of three to six mice per group analyzed on day 21.suppression. Although the precise mechanisms underlying Treg
cell-mediated protection against bone marrow pathology are cur-
rently unclear, a contribution of Treg cell-derived IL-10 was
excluded, given that anemia development was comparably
suppressed by either wild-type or IL-10-deficient Treg cells
(Figure 7A). Lack of FV specificity in Treg cells suppressing anemia
induction by pathogenic FV-specific CD4+ T cells also raised the
important question of whether or how Treg cells were being acti-
vated to mediate this suppression. Transfer of Treg cells into
Rag1/ recipients was associated with elevated expression of
ICOS and CD103, which was not, however, further enhanced by
FV infection (not shown). Similarly, transfer of EF4.1 TCRb-trans-
genic Tregcells intoRag1/ recipients led toenrichmentofclones
expressing the transgenic, rather than endogenous, TCRb chains
(Figure 7B). However, the pattern of TCRb expression in EF4.1
TCRb-transgenic Treg cells was not affected by FV infection or
the location, from which Treg cells were recovered (Figure 7B),
suggesting that Treg cell recruitment and/or expansion in the
infected bone marrow was independent of TCR specificity.790 Immunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc.Because transfer of Treg cells into lymphopenic Rag1/ re-
cipients had the potential to cause their activation irrespective
of FV-infection, we next examined whether Treg cells were
receiving additional signals originating from the infection itself.
To assess their proliferative response during the course of FV
infection, we adoptively transferred a cohort of CFSE-labeled
sensor Treg cells into Rag1/ recipients 21 days after FV infec-
tion and primary transfer of EF4.1 TCRb-transgenic CD4+ T cells.
At this time point after infection, T cell numbers in lymphoid
organs of Rag1/ recipients were equivalent to those in T cell-
replete wild-type mice, because of significant expansion of the
first cohort of EF4.1 TCRb-transgenic CD4+ T cells (Figure 2I).
The second cohort of sensor Treg cells displayed extensive pro-
liferation in the lymph nodes, spleen, and bone marrow of recip-
ient mice 3 days after transfer, with substantially fewer undivided
cells in the bone marrow than in the spleen or lymph nodes
(Figure 7C). Although this analysis did not discriminate between
enhanced division in the bone marrow or preferential migration of
divided cells into the bone marrow, it revealed that Treg cell
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of FV infection, despite the presence of substantial numbers of
T cells, and that Treg cells recovered from the bone marrow
were associated with higher proliferative history. To compare
the degree of Treg cell activation directly by the infection, the
presence of pathogenic CD4+ T cells, or the transfer into lympho-
penic Rag1/ recipients, we further examined their individual or
combined effect on Treg cell expansion. Recovery of Treg cells
from recipient mice was similar when Treg cells were transferred
into uninfected Rag1/ recipients either alone or together with
EF4.1 TCRb-transgenic CD4+ T cells or alone into FV-infected
Rag1/ recipients (Figures 7D and 7E). In contrast, recovery
of Treg cells was three and six times greater in the spleen and
bone marrow, respectively, when Treg cells were transferred to-
gether with EF4.1 TCRb-transgenic CD4+ T cells into FV-infected
Rag1/ recipients, than in any other combination (Figures 7D
and 7E). These results argued against a direct response of
Treg cells to FV infection or transfer into Rag1/ recipients
and instead indicated that Treg cell expansion and/or survival
depended on the presence of CD4+ T cells responding to FV
infection.
DISCUSSION
Strong and lasting antiviral T cell responses, which do not have an
impact on virus replication, have the potential to cause immune
pathology. Our results demonstrated that the local IFN-gproduc-
tion by virus-specific CD4+ T cells in response to unresolving FV
infection led to bone marrow pathology, which manifested as
anemia. Importantly, the severity of FV-induced CD4+ T cell-
mediated anemia critically depended on the balance between
FV-specific pathogenic CD4+ T cells and Treg cells. Moreover,
efficient suppression of FV-induced bone marrow pathology by
Treg cells did not necessitate direct viral-antigen recognition by
Treg cells because the TCR repertoire of Treg cells in virus-naive
and FV-infected mice was lacking virus-specific clones and no
conversion of FV-specific pathogenic CD4+ T cells into FoxP3-
expressing Treg cells occurred during infection.
Bone marrow pathology is a common feature of retroviral
infection in humans (Moses et al., 1998; Kulkosky et al., 2000;
Redd et al., 2007; Mlisana et al., 2008). Bone marrow dysfunction
is responsible for anemia development in approximately 60%
and 90% of acute and chronic HIV-1 infection, respectively,
and is a substantial contributor to other cytopenias, including
reduced lymphocyte production (Moses et al., 1998; Kulkosky
et al., 2000; Redd et al., 2007; Mlisana et al., 2008). It is currently
unclear whether bone marrow pathology in HIV-1 infection re-
sults from direct cytopathic effects of the virus on bone marrow
precursors or from indirect immune-mediated effects, and it is
likely that its origin is multifactorial (Molina et al., 1990; Moses
et al., 1998; Kulkosky et al., 2000; Redd et al., 2007; Mlisana
et al., 2008). Clades of HIV-1, which differ in their ability to infect
bone marrow precursors, also differ in their ability to induce
severe anemia (Redd et al., 2007; Mlisana et al., 2008). Neverthe-
less, anemia in HIV-1 infection is also observed in the absence of
bone marrow-precursor infection, indicating an indirect mecha-
nism of bone marrow dysfunction (Molina et al., 1990; Moses
et al., 1998; Kulkosky et al., 2000). Studies in mice with unresolv-
ing noncytopathic LCMV infection due to perforin deficiencyhave demonstrated that excessive virus-specific CD8+ T cell,
but not CD4+ T cell, response results in bone marrow pathology,
which is, in part, IFN-g mediated (Binder et al., 1998). Moreover,
aplastic anemia can be one of the consequences of chronic
graft-versus-host (GvH) reaction driven by histocompatibility
disparities, in the absence of infection (Sprent et al., 1994;
Chen et al., 2004). Alloantigen-specific CD4+ T cells can contrib-
ute to GvH-driven aplastic anemia either directly, by recognition
of major histocompatibility alloantigens on bone marrow precur-
sors (Sprent et al., 1994), or indirectly, by provision of help to
minor histocompatibility alloantigen-specific CD8+ T cells
(Chen et al., 2004). Similarly, we found that FV infected a large
number of bone marrow precursors with no apparent conse-
quences for bone marrow function in the absence of an adaptive
virus-specific immune response. Excessive virus-specific CD4+
T cell response was then directly responsible for development
of bone marrow pathology in an IFN-gR-dependent manner.
Collectively, these findings emphasize the harmful contribution
of indirect mechanisms of T cell-mediated immune pathology
underlying the development of anemia in chronic viral infection.
In contrast to pathology induced by direct cytopathic effects of
viral infection, T cell-mediated immune pathology is amenable to
immune regulation. Thus, Treg cells in the transferred CD4+ T cell
population from wild-type donor mice, in which the precursor
frequency of FV-specific CD4+ T cells is physiologically very
low, mediated almost complete protection from the develop-
ment of bone marrow pathology. However, Treg cell removal
from this population unmasked the pathogenic potential of
FV-specific CD4+ T cells. This balance of Treg cells and FV-
specific CD4+ T cells was markedly affected in EF4.1 TCRb-
transgenic CD4+ T cells, as a result of the increase in the
frequency of FV-specific conventional CD4+ T cell clones; such
an increase could cause bone marrow pathology despite the
presence of Treg cells. Nevertheless, Treg cell removal from
the EF4.1 TCRb-transgenic CD4+ T cell population also exacer-
bated bone marrow pathology, indicating that Treg cells
contained in this population mediated substantial, though incom-
plete, protection. Furthermore, enrichment of the EF4.1 TCRb-
transgenic CD4+ T cell population with additional Treg cells was
protective against bone marrow pathology by inhibiting the local
IFN-gproduction by pathogenic CD4+ T cells, which would other-
wise adversely affect bone marrow function. Therefore, our
results demonstrated that, at least in unresolving FV infection,
CD4+ T cell-mediated bone marrow pathology was triggered by
Treg cell insufficiency and suggested that similar mechanisms
may operate in HIV-1 infection. Although the precise fate of
Treg cells in HIV-1 infection is currently controversial, Treg cells
are susceptible to HIV-1 infection and a reduction in Treg cell
numbers and function has been correlated by certain studies
with immune activation (Kinter et al., 2004; Eggena et al., 2005).
Moreover, relative Treg cell deficiency is found in almost all pa-
tients with acquired aplastic anemia of suspected autoimmune
etiology (Solomou et al., 2007), and adoptive transfer of Treg cells
in a mouse model can ameliorate aplastic anemia driven by minor
histocompatibility differences (Chen et al., 2007). Thus, Treg cells
may play an important role in protecting the bone marrow against
a diverse spectrum of immune pathologies.
Despite the fundamental importance of Treg cells for immune
regulation, our knowledge of their antigenic specificity remainsImmunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc. 791
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that Treg cells carry a distinct TCR repertoire, which is biased
toward recognition of self-peptide-MHC II complexes with
higher-than-average avidity (Hsieh et al., 2004; Sakaguchi,
2004; Fontenot and Rudensky, 2005; Picca et al., 2006). How-
ever, a certain degree of self-reactivity is a property of all
T cells, because it represents a requirement for positive selec-
tion, and is not predictive of lack of reactivity to foreign pep-
tides. Our results with mice bearing a polyclonal TCR repertoire
with reduced diversity due to expression of a TCRb transgene,
an approach previously shown to be compatible with Treg cell
development (Hsieh et al., 2004; Pacholczyk et al., 2006), dem-
onstrated that clones with reactivity to FV env122–141 were strik-
ingly underrepresented in the Treg cell TCR repertoire of virus-
naive mice. It has been recently shown that clones reactive to
a variant of the MHC class II Ea52–68 peptide, which is a foreign
peptide for B6 mice, are similarly underrepresented in the Treg
cell pool (Burchill et al., 2008). Thus, it is conceivable that the
TCR repertoire of naturally occurring Treg cells is not normally
equipped to detect foreign peptides.
Although the emergence of pathogen-specific suppressive
T cells has been suggested by studies of chronic infection, it
has rarely been clear whether pathogen-specific suppression
is mediated by naturally occurring Treg cells or by one of
many different types of T cells with inducible suppressive activ-
ity (Mills, 2004; Rouse et al., 2006; Belkaid, 2007). A population
of T cells at the site of chronic Leishmania major infection, orig-
inating from naturally occurring Treg cells, has been shown to
react to L. major-infected dendritic cells (Suffia et al., 2006).
Although the precise nature of L. major antigens recognized
by Treg cells in this case is not known, this study emphasizes
that pathogen-specific Treg cells can be found. However,
L. major contains 8300 protein-coding genes and it is perhaps
unsurprising that the Treg cell TCR repertoire did not com-
pletely lack reactivity to products of the entire L. major
32.8Mb genome. In contrast, clones specific to FV, the 8.3 Kb
genome of which generates only three polypeptides containing
one described MHC class II Ab-restricted epitope (Iwashiro
et al., 1993), may not necessarily develop. Indeed, although
Treg cell reactivity to env122–141 was assessed more rigorously
than reactivity to other potential viral epitopes, our results
strongly suggested that FV-specific clones were not present
in the virus-naive Treg cell TCR repertoire, nor did they arise
from expansion of preexisting Treg cells or conversion of FV-
specific conventional CD4+ T cells into Treg cells in response
to FV infection. Nevertheless, our results also indicated that
reactivity to FV-derived antigens did not represent an absolute
requirement for regulation of virus-induced immune pathology.
Although the effects of lymphopenia in adoptive hosts could
not be excluded, our results showed that the most important
factor affecting expansion of Treg cell numbers during FV infec-
tion was, in fact, the concomitant response to FV of a conven-
tional effector CD4+ T cell population, which could be providing
an essential Treg cell growth factor, such as IL-2 (Almeida
et al., 2006) or inducing elevated expression of Treg cell-
stimulating self-peptide-MHC II complexes. Thus, strategies
for enhancement of Treg cell numbers or function, irrespective
of peptide specificity, may prove beneficial in the prevention
and treatment of bone marrow immune pathology.792 Immunity 29, 782–794, November 14, 2008 ª2008 Elsevier Inc.EXPERIMENTAL PROCEDURES
Mice
Inbred C57BL/6 (B6) and CD45.1-congenic B6 mice (B6.SJL-Ptprca Pep3b/
BoyJ) were originally obtained from the Jackson Laboratory (Bar Harbor,
ME, USA) and were subsequently maintained at NIMR animal facilities.
B6-backcrossed Rag1-deficient mice (Mombaerts et al., 1992) (B6.129S7-
Rag1tm1Mom/J or Rag1/), IFN-gR1-deficient mice (Huang et al., 1993)
(B6.129S7-Ifngr1tm1Agt/J or Ifngr1/), B cell-deficient mice (Kitamura et al.,
1991) (B6.129S2-Igh-6tm1Cgn/J or Igh6/, also known as mMT), IL-10-deficient
mice (Kuhn et al., 1993) (B6.129P2-Il10tm1Cgn/JLt or Il10/), FoxP3EGFP
reporter mice (B6-Foxp3tm1Mal or Foxp3egfp) (Wang et al., 2008), and Ab-
ova323-339-specific OT-II TCR-transgenic mice (Barnden et al., 1998) have
been previously described and were also maintained at NIMR animal facilities.
F-MuLV env-specific TCR-transgenic mice were generated by pronuclear mi-
croinjection of genes encoding the TCRa and TCRb chains of an env-specific
CD4+ T cell clone into fertilized B6 oocytes. In brief, we fused the SB14-31
T cell clone (Iwashiro et al., 1993), specific to env122–141 presented by MHC
II Ab, to TCRab-negative BW5147 thymoma cells to produce the 1A6 hybrid-
oma cell line, which was then used as source for RNA. TCRa and TCRb cDNAs
were cloned and inserted into the hCD2-VA expression cassette (Zhumabekov
et al., 1995), which directs expression in T cells. Specifically for the TCRb
chain, a cDNA-genomic DNA hybrid was used, in which intron 1 of the
TCRVb-encoding gene (Tcrbv1s1) was preserved. For the present study,
a TCR-transgenic line (EF4.1) expressing only the TCRb chain of the SB14-
31 clone was selected, to maintain a polyclonal TCR repertoire. Lack of trans-
genic TCRa chain expression was confirmed by crossing to B6-Rag1/ and
B6-Tcra/ mice (Philpott et al., 1992). All animal experiments were conducted
according to UK Home Office regulations and local guidelines.
Friend Virus Infection
The Friend virus (FV) used in this study was a retroviral complex of a replica-
tion-competent B-tropic helper murine leukemia virus (F-MuLV) and a replica-
tion-defective polycythemia-inducing spleen focus-forming virus (SFFVp). FV
was propagated in vivo and prepared as 10% w/v homogenate from the
spleen of 12-day-infected BALB/c mice and was free of lactate dehydroge-
nase-elevating virus (LDV). Rag1/ mice received an inoculum of 1000
spleen focus-forming units (SFFUs) of FV, injected via the tail vein in 0.1 ml
of phosphate-buffered saline. B6 and Igh6/ mice received a higher dose
of FV containing 10,000 SFFUs. We estimated cell-associated virus in in-
fected mice by flow-cytometric detection of infected cells using surface stain-
ing for the glycosylated product of the viral gag gene (glyco-Gag), using the
matrix (MA)-specific monoclonal antibody 34 (mouse IgG2b), and subsequent
use of an anti-mouse IgG2b-FITC secondary reagent (BD Biosciences, San
Jose, CA, USA).
Assessment of Primary and Secondary Lymphoid Organ Cellularity
Bone marrow cells were isolated by flushing the bone cavities of tibiae and fe-
murs and bone marrow cellularity was assessed based on the cellular contents
of these locations. Single-cell suspensions were prepared from the spleen and
lymph nodes of mice following mechanical disruption of the organs on nylon
mesh. Spleen suspensions were treated with ammonium chloride for erythro-
cyte lysis. Lymph node cellularity was calculated as the sum of the cellular con-
tents of inguinal, axillary, brachial, mesenteric and superficial cervical lymph
nodes.
Assessment of Anemia
Mice were bled by a small incision of the tail vein and blood was collected into
heparinized capillary tubes. Complete blood counts were measured on a VetS-
can HMII hematology analyzer (Abaxis, CA, USA), in accordance with the
manufacturer’s instructions.
T Cell Purification and Adoptive Transfer
CD4+ or CD25+ T cells were isolated from the spleen and lymph nodes of donor
mice, with immunomagnetic positive selection (EasySep beads, StemCell
Technologies, Vancouver, BC, Canada) according to the manufacturer’s in-
structions. Enriched cell suspensions were stained with antibodies to surface
markers and then further purified by cell sorting, performed on MoFlo cell
Immunity
Treg Cell Specificity in Retroviral Infectionsorters (Dako, Fort Collins, CO, USA). Typical cell purity after cell sorting was
higher than 98%. Purified cells (13 106 per recipient) were injected in recipient
mice via the tail vein in 0.1 ml of air-buffered IMDM.
Flow-Cytometric Analysis
Cells were stained with directly conjugated antibodies to surface markers,
obtained from eBiosciences (San Diego, CA, USA), CALTAG/Invitrogen (Carls-
bad, CA, USA), or BD Biosciences. Four- and eight-color cytometry were per-
formed on FACSCalibur (BD Biosciences) and CyAn (Dako) flow cytometers,
respectively, and analyzed with FlowJo v8.7 (Tree Star, Ashland, OR, USA)
or Summit v4.3 (Dako) analysis software, respectively. For detection of cyto-
kine synthesis, cells were stained for surface markers and stimulated for 4 hr
with PdBu and ionomycin (both at 500 ng/ml), in the presence of Monensin
(1 mg/ml). Cells were then fixed and permeabilized with buffers from eBioscien-
ces, before intracellular staining with IL-17A and IFN-g-specific antibodies
(eBiosciences). FoxP3 was detected by intranuclear staining with a FoxP3-
staining kit (eBiosciences), according to the manufacturer’s instructions.
Ab-env122-141 tetramers (kindly provided by D. Gray, University of Edinburgh,
UK) were prepared and used as previously described (Crawford et al., 1998;
MacLeod et al., 2006). In brief, cells were incubated with PE-labeled
Ab-env122-141 tetramers at 37
C in IMDM containing 5% FCS; this was
followed by staining with antibodies to surface markers, before analysis.
Analysis of Serum Cytokine Concentrations
Serum was prepared from blood samples, which were allowed to clot at 4C.
Serum cytokine concentrations were analyzed by a Bio-plex cytokine assay
(Bio-Rad Laboratories Ltd. UK) on a Luminex 100 instrument (Bio-Rad Labo-
ratories Ltd. UK) according to manufacturer’s instruction.
In Vitro T Cell Activation and Suppression
Single-cell suspensions were prepared from the spleen or lymph nodes of do-
nor mice and 0.53 106 cells per well were stimulated in 96-well plates with the
indicated amount of various stimuli. Alternatively, 0.5 3 106 naive
CD45RBhiCD25CD4+ T cells or CD25+CD4+ Treg cells, purified by flow-cyto-
metric sorting, were stimulated separately or mixed together at 1:1 ratio by
added APCs. B cells, macrophages, or dentritric cells were used as APCs
with comparable results. B cells were purified with immunomagnetic-positive
selection (EasySep beads, StemCell Technologies) from the spleen of donor
B6 or Tcra/mice. Macrophages were isolated from peritoneal cavity exudate
cells after adherence for 1 hr to plastic plates containing tissue culture. Den-
dritic cells were prepared from GM-CFS-treated bone marrow cultures. Cul-
tures were stimulated with either anti-CD3 antibodies (at 0.5 mg/ml) or with
titrated amounts of env122–141 (DEPLTSLTPRCNTAWNRLKL) or ova323–339
(ISQAVHAAHAEINEAGR) peptides. Specifically for the activation of
CD25+CD4+ Treg cells (Figures 5E and 5F), cultures were stimulated in the ab-
sence or in the presence of 20 U/ml recombinant IL-2, with similar results. T cell
activation was assessed 18 hr later by flow-cytometric detection of CD69 or
CD154 (CD40L) upregulation (both antibodies from eBiosciences), with com-
parable results. For CD154 detection, the anti-CD154 antibody was added at
the beginning of the culture. IL-2 was detected in culture supernatants
collected at 48 hr, with an AlamarBlue (Invitrogen)-based CTLL-2 assay. For as-
sessment of T cell activation on day 3, cells were labeled with CFSE before
stimulation and responding cells were identified by CFSE dilution.
Statistical Analysis
Statistics were generated by Student’s t test performed with SigmaPlot v10
software (Systat Software, San Jose, CA, USA).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and
seven figures and can be found with this article online at http://www.
immunity.com/supplemental/S1074-7613(08)00466-4.
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